ICYMI: Anti-CD4 antibody maintains viral suppression in HIV patients post ART

Patients with HIV who received the anti-CD4 antibody UB-421 after antiretroviral therapy maintained virologic suppression of less than 20 copies/mL in 94.5% of measurements during the 8-16 week study period while also maintaining CD4+ T-cell counts, according to results from a small, nonrandomized, open-label, phase 2 trial published in the New England Journal of Medicine (2019 Apr 17. doi: 10.1056/NEJMoa1802264).

Comstock/Thinkstock

We reported on this story at the 2017 Conference on Retroviruses & Opportunistic Infections before it was published in the journal. Find our coverage at the link below.

[email protected]

Patients with HIV who received the anti-CD4 antibody UB-421 after antiretroviral therapy maintained virologic suppression of less than 20 copies/mL in 94.5% of measurements during the 8-16 week study period while also maintaining CD4+ T-cell counts, according to results from a small, nonrandomized, open-label, phase 2 trial published in the New England Journal of Medicine (2019 Apr 17. doi: 10.1056/NEJMoa1802264).

Comstock/Thinkstock

We reported on this story at the 2017 Conference on Retroviruses & Opportunistic Infections before it was published in the journal. Find our coverage at the link below.

[email protected]

Patients with HIV who received the anti-CD4 antibody UB-421 after antiretroviral therapy maintained virologic suppression of less than 20 copies/mL in 94.5% of measurements during the 8-16 week study period while also maintaining CD4+ T-cell counts, according to results from a small, nonrandomized, open-label, phase 2 trial published in the New England Journal of Medicine (2019 Apr 17. doi: 10.1056/NEJMoa1802264).

Comstock/Thinkstock

We reported on this story at the 2017 Conference on Retroviruses & Opportunistic Infections before it was published in the journal. Find our coverage at the link below.

[email protected]